Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPE | Q05469 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | TRPV1 | Q8NER1 | 6/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.35 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16242494 | 0.88 | TRPV1 (0.34) | LIPEALDH1A1NPSR1TRPV1HPGD | |
| SCHEMBL1574536 | 0.77 | LIPE (0.43) | LIPEGAAALDH1A1NPSR1MEN1 | |
| SCHEMBL2955527 | 0.76 | GAA (0.43) | LIPEGAAALDH1A1NPSR1MEN1 | |
| SCHEMBL2966049 | 0.74 | GAA (0.38) | LIPEGAAALDH1A1NPSR1MEN1 | |
| SCHEMBL2962458 | 0.72 | GAA (0.35) | LIPEGAAALDH1A1NPSR1MEN1 | |
| SCHEMBL2964542 | 0.70 | GAA (0.39) | LIPEGAAALDH1A1NPSR1MEN1 | |
| SCHEMBL1573961 | 0.69 | SMN1; SMN2 (0.39) | GAAALDH1A1MEN1CYP1A2CYP2C9 | |
| SCHEMBL2956860 | 0.68 | SPR (0.36) | — | |
| SCHEMBL4244294 | 0.68 | GAA (0.46) | LIPEGAAALDH1A1NPSR1MEN1 | |
| SCHEMBL2957829 | 0.67 | GAA (0.41) | LIPEGAAALDH1A1NPSR1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1937648-B1 | DIACYL INDAZOL DERIVATIVES AS LIPASE AND PHOSPHOLIPASE INHIBITORS | SANOFI SA (FR) | 2014-11-26 | — | — | EP | disclosed |
| US-8357698-B2 | Diacyl indazole derivatives as lipase and phospholipase inhibitors | SANOFI (FR) | 2013-01-22 | — | — | US | disclosed |
| US-20100286133-A1 | Diacyl indazole derivatives as lipase and phospholipase inhibitors | SANOFI-AVENTIS (FR) | 2010-11-11 | — | — | US | disclosed |
| US-7772268-B2 | inhibitors of hormone-sensitive lipase and/or endothelial lipase; for treatment of diabetes mellitus, dyslipidemia and atherosclerotic disorders | SANOFI-AVENTIS (FR) | 2010-08-10 | — | — | US | disclosed |
| US-20080287448-A1 | Diacyl indazole derivatives as lipase and phospholipase inhibitors | SANOFI-AVENTIS (FR) | 2008-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287448-A1 | Diacyl indazole derivatives as lipase and phospholipase inhibitors | PNLIP, DAGLA, MGLL | LIPE 12/4885GAA 231/4885ALDH1A1 959/4885 |
| US-20100286133-A1 | Diacyl indazole derivatives as lipase and phospholipase inhibitors | PNLIP, DAGLA, MGLL | LIPE 12/4885GAA 231/4885ALDH1A1 959/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.